Pharmacologic Management of Patients with Hepatic and Pancreatic Diseases That Involve Immunosuppressive Therapies. Position Statement Within the Framework of the SARS-CoV-2 (COVID-19) Pandemic

Overview

Journal Rev Gastroenterol Mex (Engl Ed)

Specialty Gastroenterology

Date 2020 Jul 5

PMID 32620315

Citations 1

Authors

G Miranda-Zazueta

J A Gonzalez-Regueiro

I Garcia-Juarez

C Moctezuma-Velazquez

F J Lopez-Diaz

B Perez-Gonzalez

L F Uscanga-Dominguez

M Pelaez-Luna

Affiliations

Soon will be listed here.

Abstract

The coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus2 (SARS-CoV-2) virus. COVID-19 affected more than 6million persons worldwide in fewer than 4 months, after the report of the first cases in China in December 2019. The relation of the disease caused by SARS-Cov-2 to immunosuppressive treatment used in different gastrointestinal disorders is uncertain, resulting in debate with regard to suspending immunosuppressive therapy to improve infection outcome. Said suspension implies the inherent risk for graft rejection or autoimmune disease exacerbation that can potentially worsen the course of the infection. Based on the presently available evidence, a treatment stance has been established for patients with gastrointestinal diseases that require immunosuppressive therapy.

Citing Articles

Coronavirus disease 2019 and the pancreas.

Samanta J, Gupta R, Singh M, Patnaik I, Kumar A, Kochhar R Pancreatology. 2020; 20(8):1567-1575.

PMID: 33250089 PMC: 7550073. DOI: 10.1016/j.pan.2020.10.035.

References

Zhang C, Shi L, Wang F . Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020; 5(5):428-430. PMC: 7129165. DOI: 10.1016/S2468-1253(20)30057-1. View

Barmettler S, Ong M, Farmer J, Choi H, Walter J . Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia. JAMA Netw Open. 2019; 1(7):e184169. PMC: 6324375. DOI: 10.1001/jamanetworkopen.2018.4169. View

Vikse J, Jonsdottir K, Kvaloy J, Wildhagen K, Omdal R . Tolerability and safety of long-term rituximab treatment in systemic inflammatory and autoimmune diseases. Rheumatol Int. 2019; 39(6):1083-1090. DOI: 10.1007/s00296-019-04272-1. View

Fix O, Hameed B, Fontana R, Kwok R, McGuire B, Mulligan D . Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement. Hepatology. 2020; 72(1):287-304. PMC: 7262242. DOI: 10.1002/hep.31281. View

Ju C, Lian Q, Zhang J, Qiu T, Cai Z, Jiang W . Recommended prophylactic and management strategies for severe acute respiratory syndrome coronavirus 2 infection in transplant recipients. Chronic Dis Transl Med. 2020; 6(2):87-97. PMC: 7194659. DOI: 10.1016/j.cdtm.2020.02.003. View

Fishman J, Grossi P . Novel Coronavirus-19 (COVID-19) in the immunocompromised transplant recipient: #Flatteningthecurve. Am J Transplant. 2020; 20(7):1765-1767. PMC: 7228206. DOI: 10.1111/ajt.15890. View

Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang Y . Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. 2020; 5(1):33. PMC: 7100419. DOI: 10.1038/s41392-020-0148-4. View

Singh J, Hossain A, Kotb A, Wells G . Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis. BMC Med. 2016; 14(1):137. PMC: 5022202. DOI: 10.1186/s12916-016-0673-8. View

Boettler T, Newsome P, Mondelli M, Maticic M, Cordero E, Cornberg M . Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep. 2020; 2(3):100113. PMC: 7128473. DOI: 10.1016/j.jhepr.2020.100113. View

10.

Moon A, Webb G, Aloman C, Armstrong M, Cargill T, Dhanasekaran R . High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry. J Hepatol. 2020; 73(3):705-708. PMC: 7241346. DOI: 10.1016/j.jhep.2020.05.013. View

11.

Soliman H, Vullierme M, Maire F, Hentic O, Ruszniewski P, Levy P . Risk factors and treatment of relapses in autoimmune pancreatitis: Rituximab is safe and effective. United European Gastroenterol J. 2019; 7(8):1073-1083. PMC: 6794684. DOI: 10.1177/2050640619862459. View

12.

Okazaki K, Chari S, Frulloni L, Lerch M, Kamisawa T, Kawa S . International consensus for the treatment of autoimmune pancreatitis. Pancreatology. 2016; 17(1):1-6. DOI: 10.1016/j.pan.2016.12.003. View

13.

Garcia-Tsao G, Abraldes J, Berzigotti A, Bosch J . Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2016; 65(1):310-335. DOI: 10.1002/hep.28906. View

14.

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J . Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720. PMC: 7092819. DOI: 10.1056/NEJMoa2002032. View

15.

. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018; 69(2):406-460. DOI: 10.1016/j.jhep.2018.03.024. View

16.

Holshue M, DeBolt C, Lindquist S, Lofy K, Wiesman J, Bruce H . First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020; 382(10):929-936. PMC: 7092802. DOI: 10.1056/NEJMoa2001191. View

17.

DAntiga L . Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic. Liver Transpl. 2020; 26(6):832-834. DOI: 10.1002/lt.25756. View

18.

. EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol. 2015; 63(4):971-1004. DOI: 10.1016/j.jhep.2015.06.030. View

19.

Wolfe F, Caplan L, Michaud K . Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006; 54(2):628-34. DOI: 10.1002/art.21568. View

20.

Bhoori S, Rossi R, Citterio D, Mazzaferro V . COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy. Lancet Gastroenterol Hepatol. 2020; 5(6):532-533. PMC: 7146678. DOI: 10.1016/S2468-1253(20)30116-3. View